{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:35:41Z","timestamp":1776321341070,"version":"3.50.1"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and ICT of Republic of Korea","award":["2018R1A5A2021242"],"award-info":[{"award-number":["2018R1A5A2021242"]}]},{"name":"Ministry of Science and ICT of Republic of Korea","award":["2021R1F1A1056393"],"award-info":[{"award-number":["2021R1F1A1056393"]}]},{"name":"Ministry of Research and Technology\/National Agency for Research and Innovation of Indonesia","award":["8478\/UN3.1.1\/LT\/2019"],"award-info":[{"award-number":["8478\/UN3.1.1\/LT\/2019"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Diabetes mellitus (DM), a common comorbidity in tuberculosis (TB) patients, can alter the pharmacokinetics (PK) of TB drugs. Additionally, clinical and demographic differences may contribute to interethnic PK variability. However, current WHO-recommended doses for pyrazinamide (PZA) do not account for those factors. We aimed to evaluate factors related to interindividual variability (IIV) and interethnic differences in the PK of PZA between Korean and Indonesian patients with TB. Demographics, clinical characteristics, and PZA concentrations obtained from hospitals in both countries were used for model establishment. Population PK models were developed using the nonlinear mixed-effect method. A Monte Carlo simulation was performed sequentially to evaluate optimal PZA dosing strategies. A one-compartment model with allometric scaling adequately described the PK of PZA. Internal validation of the model showed good performance. No significant interethnic differences in PK parameters were observed. There were 23% and 26% increases in apparent clearance (CL\/F) of Indonesian patients with DM (CL\/F 3.18\u2009L\/h) and Korean patients aged\u2009&gt;\u200960 years with DM (CL\/F 3.5). PZA doses of 1000\u20131250\u2009mg for patients of bodyweight\u2009&lt;\u200940\u2009kg and 1250\u2009mg for older patients with DM in this weight band had a 90% probability of attaining the target AUC\n                    <jats:sub>0\u201324<\/jats:sub>\n                    \u2009\u2265\u2009363 mg\u00b7h\/L These findings indicate that DM strongly influenced IIV, particularly in older patients. We recommend higher PZA doses for patients &lt;40\u2009kg and older patients with DM in this weight band. Our model provides a basis for implementing model-informed precision dosing-based therapeutic drug monitoring in both ethnicities.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0340133","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:31:07Z","timestamp":1769711467000},"page":"e0340133","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-1965","authenticated-orcid":true,"given":"Rannissa Puspita","family":"Jayanti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-1123","authenticated-orcid":true,"given":"Yong-Soon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-5619","authenticated-orcid":true,"given":"Soedarsono","family":"Soedarsono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyeon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Hyoung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jick Hwan","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni Made","family":"Mertaniasih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0487-4763","authenticated-orcid":true,"given":"Tutik","family":"Kusmiati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariani","family":"Permatasari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Yuliwulandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryunha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0087-631X","authenticated-orcid":true,"given":"Hyeon-Jeong","family":"Seong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Lyul","family":"Ghim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Gook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the cPMTb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"pone.0340133.ref001","volume-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2023"},{"key":"pone.0340133.ref002","article-title":"Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections","author":"F Ntoumi","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0340133.ref003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4046\/trd.2022.0111","article-title":"Tuberculosis: Republic of Korea, 2021","volume":"86","author":"J Min","year":"2023","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"1","key":"pone.0340133.ref004","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Y Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"pone.0340133.ref005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF00558302","article-title":"Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects","volume":"36","author":"C Lacroix","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"pone.0340133.ref006","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.202401-0165OC","article-title":"Pyrazinamide safety, efficacy, and dosing for treating drug-susceptible pulmonary tuberculosis: a phase 3, randomized controlled clinical trial","volume":"210","author":"AY Xu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pone.0340133.ref007","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-014-0209-3","article-title":"Interethnic differences in pharmacokinetics of antibacterials","volume":"54","author":"D Tsai","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"pone.0340133.ref008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02625-16","article-title":"Population pharmacokinetics of pyrazinamide in patients with tuberculosis","volume":"61","author":"A Alsultan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0340133.ref009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00490-17","article-title":"Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and -resistant tuberculosis","volume":"61","author":"MT Chirehwa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0340133.ref010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00228-003-0653-8","article-title":"Xanthine oxidase activity is influenced by environmental factors in Ethiopians","volume":"59","author":"E Aklillu","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"pone.0340133.ref011","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2337\/dc17-1434","article-title":"Elevated serum xanthine oxidase activity is associated with the development of type 2 diabetes: a prospective cohort study","volume":"41","author":"X Li","year":"2018","journal-title":"Diabetes Care"},{"key":"pone.0340133.ref012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-9-81","article-title":"The impact of diabetes on tuberculosis treatment outcomes: a systematic review","volume":"9","author":"MA Baker","year":"2011","journal-title":"BMC Med"},{"issue":"3","key":"pone.0340133.ref013","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/thoraxjnl-2015-207686","article-title":"The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study","volume":"72","author":"YS Yoon","year":"2017","journal-title":"Thorax"},{"issue":"11","key":"pone.0340133.ref014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01383-18","article-title":"Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment","volume":"62","author":"O Alfarisi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pone.0340133.ref015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","article-title":"Population pharmacokinetics and bayesian dose adjustment to advance TDM of anti-TB drugs","volume":"60","author":"MGG Sturkenboom","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"pone.0340133.ref016","doi-asserted-by":"crossref","first-page":"566608","DOI":"10.3389\/fimmu.2020.566608","article-title":"Perspective for precision medicine for tuberculosis","volume":"11","author":"C Lange","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"pone.0340133.ref017","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3390\/pharmaceutics14050990","article-title":"Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management","volume":"14","author":"RP Jayanti","year":"2022","journal-title":"Pharmaceutics"},{"key":"pone.0340133.ref018","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update.","author":"WHO","year":"2017"},{"issue":"7","key":"pone.0340133.ref019","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00003-22","article-title":"Population pharmacokinetic modelling and limited sampling strategies for therapeutic drug monitoring of pyrazinamide in patients with tuberculosis","volume":"66","author":"R Abolhassani-Chimeh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0340133.ref020","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1128\/AAC.00480-16","article-title":"HIV-1 coinfection does not reduce exposure to rifampin, isoniazid, and pyrazinamide in South African tuberculosis outpatients","volume":"60","author":"N Rockwood","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0340133.ref021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00046-21","article-title":"Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients coinfected with HIV and implications for individualized dosing","volume":"65","author":"J Sundell","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0340133.ref022","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/bcp.14522","article-title":"Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study","volume":"87","author":"Y Gao","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0340133.ref023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry","volume":"102","author":"H-J Kim","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"pone.0340133.ref024","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"BJ Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"pone.0340133.ref025","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/ndt\/gft003","article-title":"Pro: estimating GFR using the chronic kidney disease epidemiology collaboration (CKD-EPI) 2009 creatinine equation: the time for change is now","volume":"28","author":"LA Inker","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0340133.ref026","article-title":"Estimated lean body mass as an index for normalization of body fluid volumes in humans","volume":"247","author":"P Boer","year":"1984","journal-title":"Am J Physiol"},{"issue":"9","key":"pone.0340133.ref027","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"JG Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0340133.ref028","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"A Alsultan","year":"2014","journal-title":"Drugs"},{"key":"pone.0340133.ref029","doi-asserted-by":"crossref","first-page":"1116226","DOI":"10.3389\/fphar.2023.1116226","article-title":"Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance","volume":"14","author":"R Kim","year":"2023","journal-title":"Front Pharmacol"},{"issue":"10","key":"pone.0340133.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"P Denti","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"pone.0340133.ref031","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","article-title":"How important are gender differences in pharmacokinetics?","volume":"41","author":"B Meibohm","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"pone.0340133.ref032","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1128\/AAC.05526-11","article-title":"Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines","volume":"56","author":"H McIlleron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0340133.ref033","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12879-016-1470-x","article-title":"Na\u00efve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis","volume":"16","author":"T Pouplin","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"11","key":"pone.0340133.ref034","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1345\/aph.1E259","article-title":"Population pharmacokinetics II: estimation methods","volume":"38","author":"EI Ette","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"9","key":"pone.0340133.ref035","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"DR Mould","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"pone.0340133.ref036","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00228-022-03362-7","article-title":"Influence of N-acetyltransferase 2 (NAT2) genotype\/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models","volume":"78","author":"Chaithra","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"pone.0340133.ref037","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jcph.1931","article-title":"Isoniazid population pharmacokinetics and dose recommendation for Korean patients with tuberculosis based on target attainment analysis","volume":"61","author":"Y-S Cho","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"pone.0340133.ref038","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijid.2022.01.003","article-title":"Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis","volume":"117","author":"S Soedarsono","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"4","key":"pone.0340133.ref039","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s13318-018-00540-w","article-title":"Population pharmacokinetic modelling of pyrazinamide and pyrazinoic acid in patients with multi-drug resistant tuberculosis","volume":"44","author":"P Mugabo","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"pone.0340133.ref040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/pgs-2018-0166","article-title":"Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis","volume":"20","author":"A Naidoo","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"6","key":"pone.0340133.ref041","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.890","article-title":"Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?","volume":"9","author":"O Olafuyi","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"12","key":"pone.0340133.ref042","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1093\/jac\/dkz368","article-title":"Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients","volume":"74","author":"CM Mtabho","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"pone.0340133.ref043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258809","article-title":"Variation of tuberculosis prevalence across diagnostic approaches and geographical areas of Indonesia","volume":"16","author":"A Noviyani","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"pone.0340133.ref044","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4239\/wjd.v8.i6.278","article-title":"Treatment of type 2 diabetes mellitus in the elderly","volume":"8","author":"FD Yakary\u0131lmaz","year":"2017","journal-title":"World J Diabetes"},{"issue":"8","key":"pone.0340133.ref045","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/dmd.121.000389","article-title":"Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug","volume":"49","author":"Z Hussain","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"pone.0340133.ref046","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1464-5491.2005.01630.x","article-title":"Glycaemic control in relation to xanthine oxidase and antioxidant indices in Malaysian Type 2 diabetes patients","volume":"22","author":"UR Kuppusamy","year":"2005","journal-title":"Diabet Med"},{"issue":"7","key":"pone.0340133.ref047","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/1071576031000107344","article-title":"Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice","volume":"37","author":"S Matsumoto","year":"2003","journal-title":"Free Radic Res"},{"issue":"4","key":"pone.0340133.ref048","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1128\/AAC.01866-12","article-title":"A novel mechanism underlies the hepatotoxicity of pyrazinamide","volume":"57","author":"T-Y Shih","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0340133.ref049","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijid.2020.05.080","article-title":"A novel risk factor for predicting anti-tuberculosis drug resistance in patients with tuberculosis complicated with type 2 diabetes mellitus","volume":"97","author":"M Lyu","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"6","key":"pone.0340133.ref050","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4103\/2230-8210.167553","article-title":"Diabetes mellitus in elderly","volume":"19","author":"F Chentli","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"issue":"7","key":"pone.0340133.ref051","article-title":"The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis","volume":"15","author":"BS Kwon","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"pone.0340133.ref052","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"JJ Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pone.0340133.ref053","doi-asserted-by":"crossref","first-page":"106914","DOI":"10.1016\/j.ijantimicag.2023.106914","article-title":"Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review","volume":"62","author":"RH Chen","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"pone.0340133.ref054","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/cid\/ciz942","article-title":"Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis","volume":"70","author":"J-WC Alffenaar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0340133.ref055","doi-asserted-by":"crossref","first-page":"102325","DOI":"10.1016\/j.tube.2023.102325","article-title":"Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosis","volume":"139","author":"S Soedarsono","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"issue":"2","key":"pone.0340133.ref056","doi-asserted-by":"crossref","first-page":"107034","DOI":"10.1016\/j.ijantimicag.2023.107034","article-title":"Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure","volume":"63","author":"PQ Hoa","year":"2024","journal-title":"Int J Antimicrob Agents"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0347490","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000}}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:31:17Z","timestamp":1769711477000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340133"}},"subtitle":[],"editor":[{"given":"Mehnath","family":"Sivaraj","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340133","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}